 |
|
Efficacy of Leuprolide Therapy in Children With Central Precocious Puberty
Michael S. Kappy, MD, PhD;
Thomas Stuart, RN, BSN;
Alvin Perelman, MD
Am J Dis Child. 1988;142(10):1061-1064.
Abstract
• Eight girls with central precocious puberty were treated with the long-acting gonadotropin releasing hormone analogue leuprolide acetate (Lupron) for a period of six to 18 months. Suppression of gonadotropin and estradiol secretion and regression of secondary sexual characteristics and menses were observed while patients received a subcutaneous dose of 35 to 40 µg/kg/d. Growth velocity was slowed in all but one patient, and the rate of skeletal maturation was slowed even more, resulting in a stabilization or improvement in predicted adult height. There were no major side effects. Although the long-term effects of leuprolide therapy cannot be determined with this study, it appears to be efficacious in the treatment of central precocious puberty.
(AJDC 1988;142:1061-1064)
Author Affiliations
From Children's Health Center of St Joseph's Hospital, Phoenix (Dr Kappy and Mr Stuart), and Phoenix Children's Hospital (Dr Perelman).
Footnotes
Accepted for publication July 16, 1988.
Reprint requests to Children's Health Center of St Joseph's Hospital, 350 W Thomas, Phoenix, AZ 85013 (Dr Kappy).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
A Single Luteinizing Hormone Determination 2 Hours after Depot Leuprolide Is Useful for Therapy Monitoring of Gonadotropin-Dependent Precocious Puberty in Girls
Brito et al.
J. Clin. Endocrinol. Metab. 2004;89:4338-4342.
ABSTRACT
| FULL TEXT
A Single Sample Subcutaneous Luteinizing Hormone (LH)-Releasing Hormone (LHRH) Stimulation Test for Monitoring LH Suppression in Children with Central Precocious Puberty Receiving LHRH Agonists
J. Clin. Endocrinol. Metab. 1999;84:4536-4540.
ABSTRACT
| FULL TEXT
|
